These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 24685602)

  • 1. Severe fibrosis in patients with recurrent hepatitis C after liver transplantation: a French experience on 250 patients over 15 years (the Orfèvre study).
    Dumortier J; Salamé E; Roche B; Hurtova M; Conti F; Radenne S; Vanlemmens C; Pageaux GP; Saliba F; Samuel D; Compagnon P; Neau-Cransac M; Calmus Y; Guillaud O; Gugenheim J; Altieri M; Durand F; Hardwigsen J; Lorho R; Dharancy S; Leroy V; Di Giambattista F; Duvoux C
    Clin Res Hepatol Gastroenterol; 2014 Jun; 38(3):292-9. PubMed ID: 24685602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study.
    Belli LS; Burroughs AK; Burra P; Alberti AB; Samonakis D; Cammà C; De Carlis L; Minola E; Quaglia A; Zavaglia C; Vangeli M; Patch D; Dhillon A; Cillo U; Guido M; Fagiuoli S; Giacomoni A; Slim OA; Airoldi A; Boninsegna S; Davidson BR; Rolles K; Pinzello G
    Liver Transpl; 2007 May; 13(5):733-40. PubMed ID: 17370330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single center.
    Walter T; Dumortier J; Guillaud O; Hervieu V; Scoazec JY; Boillot O
    Liver Transpl; 2007 Feb; 13(2):294-301. PubMed ID: 17256784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 7-gene signature of the recipient predicts the progression of fibrosis after liver transplantation for hepatitis C virus infection.
    do O NT; Eurich D; Schmitz P; Schmeding M; Heidenhain C; Bahra M; Trautwein C; Neuhaus P; Neumann UP; Wasmuth HE
    Liver Transpl; 2012 Mar; 18(3):298-304. PubMed ID: 22139994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Explanted liver inflammatory grade predicts fibrosis progression in hepatitis C recurrence.
    Ghabril M; Dickson RC; Krishna M; Machicao V; Aranda-Michel J; Bonatti H; Nguyen JH
    Liver Transpl; 2011 Jun; 17(6):685-94. PubMed ID: 21618689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age.
    Selzner N; Girgrah N; Lilly L; Guindi M; Selzner M; Therapondos G; Adeyi O; McGilvray I; Cattral M; Greig PD; Grant D; Levy G; Renner EL
    Liver Transpl; 2008 Dec; 14(12):1778-86. PubMed ID: 19025914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming growth factor β1 polymorphisms and progression of graft fibrosis after liver transplantation for hepatitis C virus--induced liver disease.
    Eurich D; Bahra M; Boas-Knoop S; Lock JF; Golembus J; Neuhaus R; Neuhaus P; Neumann UP
    Liver Transpl; 2011 Mar; 17(3):279-88. PubMed ID: 21384510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up.
    Jain A; Singhal A; Kashyap R; Safadjou S; Ryan CK; Orloff MS
    Transplantation; 2011 Aug; 92(4):453-60. PubMed ID: 21799468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin blockade does not affect fibrosis progression in recurrent hepatitis C after liver transplantation.
    Guillaud O; Gurram KC; Puglia M; Lilly L; Adeyi O; Renner EL; Selzner N
    Transplant Proc; 2013; 45(6):2331-6. PubMed ID: 23953545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying the superior measure of rapid fibrosis for predicting premature cirrhosis after liver transplantation for hepatitis C.
    Howell J; Sawhney R; Angus P; Fink M; Jones R; Wang BZ; Visvanathan K; Crowley P; Gow P
    Transpl Infect Dis; 2013 Dec; 15(6):588-99. PubMed ID: 24028328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C.
    Rayhill SC; Wu YM; Katz DA; Voigt MD; Labrecque DR; Kirby PA; Mitros FA; Kalil RS; Miller RA; Stolpen AH; Schmidt WN
    Transplantation; 2007 Aug; 84(3):331-9. PubMed ID: 17700157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection.
    Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Cabrera R; Shuster JJ; Theriaque D; Reed AI; Hemming AW; Liu C; Crawford JM; Nelson DR
    Liver Transpl; 2004 Oct; 10(10):1240-7. PubMed ID: 15376304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection.
    Berres ML; Trautwein C; Schmeding M; Eurich D; Tacke F; Bahra M; Neuhaus P; Neumann UP; Wasmuth HE
    Hepatology; 2011 Feb; 53(2):596-603. PubMed ID: 21274880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation.
    Poujol-Robert A; Boëlle PY; Conti F; Durand F; Duvoux C; Wendum D; Paradis V; Mackiewicz V; Chazouillères O; Corpechot C; Poupon R
    Clin Res Hepatol Gastroenterol; 2014 Oct; 38(5):570-6. PubMed ID: 25130796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.
    de Arias AE; Haworth SE; Belli LS; Burra P; Pinzello G; Vangeli M; Minola E; Guido M; Boccagni P; De Feo TM; Torelli R; Cardillo M; Scalamogna M; Poli F
    Liver Transpl; 2009 Apr; 15(4):390-9. PubMed ID: 19326408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C.
    Machicao VI; Bonatti H; Krishna M; Aqel BA; Lukens FJ; Nguyen JH; Rosser BG; Satyanarayana R; Grewal HP; Hewitt WR; Harnois DM; Crook JE; Steers JL; Dickson RC
    Transplantation; 2004 Jan; 77(1):84-92. PubMed ID: 14724440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C.
    Wali M; Harrison RF; Gow PJ; Mutimer D
    Gut; 2002 Aug; 51(2):248-52. PubMed ID: 12117889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peritransplant absolute lymphocyte count as a predictive factor for advanced recurrence of hepatitis C after liver transplantation.
    Nagai S; Yoshida A; Kohno K; Altshuler D; Nakamura M; Brown KA; Abouljoud MS; Moonka D
    Hepatology; 2014 Jan; 59(1):35-45. PubMed ID: 23728831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation.
    Manousou P; Burroughs AK; Tsochatzis E; Isgro G; Hall A; Green A; Calvaruso V; Ma GL; Gale J; Burgess G; O'Beirne J; Patch D; Thorburn D; Leandro G; Dhillon AP
    J Hepatol; 2013 May; 58(5):962-8. PubMed ID: 23262247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.
    Burak KW; Kremers WK; Batts KP; Wiesner RH; Rosen CB; Razonable RR; Paya CV; Charlton MR
    Liver Transpl; 2002 Apr; 8(4):362-9. PubMed ID: 11965581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.